{{Rsnum
|rsid=5568
|Gene=SLC6A2
|Chromosome=16
|position=55696212
|Orientation=plus
|GMAF=0.2755
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
|Gene_s=SLC6A2
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 46.0 | 45.1 | 8.8
| HCB | 45.3 | 42.3 | 12.4
| JPT | 46.9 | 44.2 | 8.8
| YRI | 89.1 | 10.9 | 0.0
| ASW | 70.2 | 26.3 | 3.5
| CHB | 45.3 | 42.3 | 12.4
| CHD | 49.5 | 44.0 | 6.4
| GIH | 51.5 | 41.6 | 6.9
| LWK | 94.5 | 5.5 | 0.0
| MEX | 41.4 | 51.7 | 6.9
| MKK | 75.0 | 23.7 | 1.3
| TSI | 34.3 | 47.1 | 18.6
| HapMapRevision=28
}}A allele associated with better response to treatment of [[ADHD]] with [[atomoxetine]]. {{PMID|19387424}}

{{PMID Auto
|PMID=20863575
|Title=Lack of association between response of OROS-methylphenidate and norepinephrine transporter (SLC6A2) polymorphism in Korean ADHD
}}

{{PMID Auto
|PMID=16380908
|Title=Preferential transmission of paternal alleles at risk genes in attention-deficit/hyperactivity disorder.
|OA=1
}}

{{PMID Auto
|PMID=18937309
|Title=Sexually dimorphic effects of four genes (COMT, SLC6A2, MAOA, SLC6A4) in genetic associations of ADHD: a preliminary study.
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}